DATASHEET
Host:
Rabbit
Target Protein:
Human IgM
Clonality:
Recombinant
Isotype:
IgG
Swiss Prot:
P01871
Source:
Native Human IgM
Purification:
Purified by Protein A.
Storage Buffer:
0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol
Storage:
Store at -20°C for 12 months.
Background:
Immunoglobulin M (IgM) forms polymers where multiple immunoglobulins are covalently linked together with disulfide bonds, normally as a pentamer and the J chain is attached to most pentamers. It has a large molecular mass of approximately 900 kD. Due to its polymeric nature, IgM possesses high avidity, and is particularly effective at complement activation. It is sometimes called a "natural antibody", but it is likely that the antibodies arise due to sensitization in the very young to antigens that are naturally occurring in nature. IgM is the first immunoglobulin expressed by mature B cells. IgM antibodies appear early in the course of an infection and usually do not reappear after further exposure. IgM antibodies do not pass across the human placenta. These two biological properties of IgM make it useful in the diagnosis of infectious diseases. Demonstrating IgM antibodies in patients serum indicates recent or in serum from a neonate intrauterine infection such as congenital rubella.
VALIDATION IMAGES
Paraformaldehyde-fixed and paraffin-embedded Human tonsil tissue incubated with Human IgM (4C2) Monoclonal Antibody (bsm-52860R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.
Paraformaldehyde-fixed, paraffin embedded Human tonsil; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with Human IgM (4C2) Monoclonal Antibody, Unconjugated (bsm-52860R) at 1:200 overnight at 4°C, DAB staining.
Lane 1: Human Serum probed with Human IgM Monoclonal Antibody, Unconjugated (bsm-52860R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.